摘要
目的观察血管性痴呆伴精神行为症状患者采用多奈哌齐联合奥氮平治疗的临床疗效及安全性。方法将本院收治的140例血管性痴呆伴精神行为症状患者随机分为观察组(予以多奈哌齐与奥氮平联合治疗,n=70)和对照组(予以多奈哌齐单用治疗,n=70),对比两组患者用药前后简明精神病评定量表评分(BPRS)、痴呆简易筛查量表评分(BSSD)、Cohen-Mansfield激越问卷评分(CMAI)及药物不良反应发生率。结果组间BPRS、BSSD、CMAI评分变化情况及药物不良反应发生率对比,观察组患者所得结果比对照组所得结果更具有优越性,实验数据对比,差异有统计学意义(P<0.05)。结论多奈哌齐联合奥氮平治疗在血管性痴呆伴精神行为症状患者中的应用效果显著,有效改善了疾病临床表现。
Objective To observe the clinical efficacy and safety of donepezil combined with olanzapine in patients with vascular dementia and psychotic symptoms. Methods 140 patients with vascular dementia and psychotic symptoms were randomly divided into observation group （treated with donepezil and olanzapine, n = 70） and control group （treated with donepezil alone, n = 70）. The incidence of adverse events such as BPRS, BSSD and CMAI were compared between the two groups before and after treatment. Results The scores of BPRS, BSSD and CMAI in the group were compared with those of the control group. The results of the observation group were superior to the control group, and the difference was Statistically significant （P 〈 0.05）. Conelusion Donepezil combined with olanzapine has a significant effect in the treatment of patients with vascular dementia and psychotic symptoms, which can effectively improve the clinical manifestations of the disease.
出处
《中国卫生标准管理》
2017年第17期60-62,共3页
China Health Standard Management
